Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 10, 2007

OncoMethylome Enhances Pharmacogenomic Services in Deal with BioTrove

  • OncoMethylome Sciences will use BioTrove's OpenArray™ PCR screening technology in the development of DNA gene methylation cancer biomarkers.

    OncoMethylome products are designed to detect cancer cells and predict their response to cancer therapy by identifying specific methylation markers in patient DNA samples through PCR. "We look forward to enhancing our pharmacogenomic services with the BioTrove OpenArray system, which enables us to test our many proprietary methylation markers on clinical samples in a fast, high-throughput manner," says Wim Van Criekinge, vp, biomarker and pharmacogenomics research, OncoMethylome.

    Under the terms of the multiyear agreement, BioTrove will supply OncoMethylome with OpenArray nanoplates and instrumentation for use in R&D of DNA methylation-based biomarkers.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »